Loading provider…
Loading provider…
Hematology & Oncology Physician in Louisville, KY
NPI: 1144209982Primary Practice Location
UNIVERSITY OF LOUISVILLE HOSPITAL
530 S Jackson St, Louisville, KY
Primary Employer
Ulrf Oncology
uoflhealth.org
HQ Phone
Get MD Vivek's Phone Numberphone_androidMobile
Get MD Vivek's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardKY State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 152 | 501 |
| 2 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 22 | 41 |
| 3 | 99205New patient office or other outpatient visit, typically 60 minutes | 22 | 22 |
| 4 | 99222Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 13 | 14 |
| 5 | 99221Initial hospital inpatient care, typically 30 minutes per day | 12 | 14 |
Antiplatelet Agents in Sepsis-Putting it all together: A Call to Action.
Authors: Tiwari, Nishant R, Chaudhari, Kaustubh S, Sharma, Richa, Haas, Kevin P, Sharma, Vivek R
Journal: Indian J Crit Care Med
COVID-19 and thrombotic microangiopathies.
Authors: Tiwari, Nishant R, Phatak, Sanat, Sharma, Vivek R, Agarwal, Sanjay K
Journal: Thromb Res
Publication Date: 2021-04-20
Lead Sponsor: University of Louisville
Collaborators: James Graham Brown Cancer Center
Intervention / Treatment: RADIATION: Stereotactic Body Radiation Therapy, DRUG: Folfirinox
Lead Sponsor: Hutchison Medipharma Limited
Intervention / Treatment: DRUG: Placebo, DRUG: Fruquintinib
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Magnetic Resonance Imaging, DRUG: Sunitinib Malate, BIOLOGICAL: Nivolumab, OTHER: Laboratory Biomarker Analysis, DRUG: Osimertinib, PROCEDURE: Biospecimen Collection, DRUG: Dabrafenib, DRUG: Crizotinib, DRUG: Sapanisertib, DRUG: Taselisib, PROCEDURE: Computed Tomography, BIOLOGICAL: Trastuzumab, DRUG: Trametinib, PROCEDURE: Multigated Acquisition Scan, DRUG: Palbociclib, DRUG: Afatinib, DRUG: Ulixertinib, OTHER: Cytology Specimen Collection Procedure, DRUG: Dasatinib, DRUG: Vismodegib, DRUG: Afatinib Dimaleate, DRUG: Adavosertib, PROCEDURE: Biopsy Procedure, DRUG: Defactinib, PROCEDURE: Radionuclide Imaging, BIOLOGICAL: Trastuzumab Emtansine, DRUG: Copanlisib, PROCEDURE: Echocardiography Test, DRUG: PI3K-beta Inhibitor GSK2636771, DRUG: Larotrectinib, BIOLOGICAL: Relatlimab, DRUG: Copanlisib Hydrochloride, DRUG: Capivasertib, DRUG: Erdafitinib, DRUG: Larotrectinib Sulfate, DRUG: Binimetinib, BIOLOGICAL: Pertuzumab, DRUG: Ipatasertib, DRUG: Dabrafenib Mesylate, DRUG: Defactinib Hydrochloride, DRUG: Fexagratinib, PROCEDURE: Radiologic Examination